Shockwave Medical Valuation
Is SWAV * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SWAV * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SWAV * (MX$3700) is trading below our estimate of fair value (MX$4053.98)
Significantly Below Fair Value: SWAV * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SWAV *?
Other financial metrics that can be useful for relative valuation.
What is SWAV *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$6.47b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 9.4x |
Enterprise Value/EBITDA | 36.6x |
PEG Ratio | 2x |
Price to Earnings Ratio vs Peers
How does SWAV *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 72.8x | ||
MASI Masimo | 88.2x | 28.9% | US$7.2b |
688617 APT Medical | 58.5x | 27.0% | CN¥31.2b |
GMED Globus Medical | 56.7x | 31.6% | US$6.9b |
PEN Penumbra | 87.7x | 24.4% | US$8.0b |
SWAV * Shockwave Medical | 26.5x | 13.5% | Mex$6.5b |
Price-To-Earnings vs Peers: SWAV * is good value based on its Price-To-Earnings Ratio (26.5x) compared to the peer average (43.4x).
Price to Earnings Ratio vs Industry
How does SWAV *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: SWAV * is good value based on its Price-To-Earnings Ratio (26.5x) compared to the Global Medical Equipment industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is SWAV *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 26.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SWAV *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.